Deutsche Bank today announced its appointment as sponsored depositary
bank for the Level III NASDAQ-listed American Depositary Receipt (ADR)
program of Hutchison China MediTech Limited (Chi-Med).
Chi-Med (NASDAQ: HCM) is a China-based, globally-focused healthcare
group which researches, develops, manufactures and sells pharmaceuticals
and health-related consumer products. Its Innovation Platform focuses on
discovering and developing innovative therapeutics in oncology and
autoimmune diseases for the global market. Its Commercial Platform
manufactures, markets, and distributes prescription drugs and consumer
health products in China. Chi-Med is majority owned by the multinational
conglomerate CK Hutchison Holdings Limited.*
“We are delighted to be appointed as depositary bank for Hutchison China
MediTech Limited’s NASDAQ-listed ADR program,” said David West, Head of
Issuer Services, Asia Pacific at Deutsche Bank. “Deutsche Bank is
committed to providing Chi-Med with the highest quality ADR services for
their newly launched ADR program.”
Deutsche Bank’s Depositary Receipts team is part of the Issuer Services
business within Global Securities Services.
In addition to specializing in administering cross-border equity
structures such as American and global depositary receipts and global
registered shares, Issuer Services provides corporates, financial
institutions, hedge funds and supranational agencies around the world
with trustee, agency, escrow and related services. The Bank offers a
very broad range of services for diverse products, from complex
securitizations and project finance to syndicated loans, debt exchanges
and restructurings.
*Source: Hutchison China MediTech Limited (March 2016)
About Deutsche Bank:
Deutsche Bank provides commercial and investment banking, retail
banking, transaction banking and asset and wealth management products
and services to corporations, governments, institutional investors,
small and medium-sized businesses, and private individuals. Deutsche
Bank is Germany’s leading bank, with a strong position in Europe and a
significant presence in the Americas and Asia Pacific.
The Depositary Receipts have been registered pursuant to the US
Securities Act of 1933. The investment or investment service which is
the subject of this notice is not available to retail clients as defined
by the UK Financial Conduct Authority. This notice has been approved
and/or communicated by Deutsche Bank AG New York. The services described
in this notice are provided by Deutsche Bank Trust Company Americas
(Deutsche Bank) or by its subsidiaries and/or affiliates in accordance
with appropriate local registration and regulation. Deutsche Bank is
providing the attached notice strictly for information purposes and
makes no claims or statement, nor does it warrant or in any way
represent, as to the accuracy or completeness of the details contained
herein or therein. This announcement appears as a matter of record only.
Neither this announcement nor the information contained herein
constitutes an offer or solicitation by Deutsche Bank or any other
issuer or entity for the purchase or sale of any securities nor does it
constitute a solicitation to any person in any jurisdiction where
solicitation would be unlawful. No part of this notice may be copied or
reproduced in any way without the prior written consent of Deutsche
Bank. Past results are not an indication of future performance.
Copyright© March 2016 Deutsche Bank AG. All rights reserved.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160323005907/en/
Copyright Business Wire 2016